2024 RN NCCN Guidelines SCL29

123456789101112131415161718
Across
  1. 3. Emetic risk day 1
  2. 7. Durvalumab may cause this along with other neurological disorders
  3. 10. May be used to prevent myeloid suppression
  4. 11. National Comprehensive Cancer Network
  5. 12. Carboplatin is known to deplete these, requiring replacement
  6. 13. Carboplatin uses this to formulate a safe renal dose
  7. 14. Durvalumab may cause this type of a reaction
  8. 16. This agent may cause anaphylaxis. Welch Allen has a vital signs programmed for this drug
  9. 18. Emetic risk of monoclonal antibody, alone
Down
  1. 1. This agent does not require special tubing or filter
  2. 2. This agent may require systemic corticosteroids
  3. 4. Both Carboplatin and Etoposide are considered to be an
  4. 5. This reaction may with cumulative doses of Carboplatin
  5. 6. Inflammation of the lung; can be an adverse side effect Durvlumab
  6. 8. Primary, extensive stage
  7. 9. Small Cell Lung Cancer
  8. 15. Equation used to dose Carboplatin
  9. 17. Immune Related Adverse Events